Proteomics International focused on first commercial sales for PromarkerD in USA

Proteomics International managing director Dr Richard Lipscombe introduces Proactive to its work in diagnostics, specifically in the area of precision medicine. Lipscombe highlights the three biomarkers for Diabetic Kidney Disease identified by the company’s Promarker™ Platform and which have been verified, validated and developed into a commercially available test: PromarkerD. The company recently signed a binding and exclusive letter of intent (LOI) with Sonic Healthcare USA, Inc. for an exclusive licence for use of its PromarkerD test for diabetic kidney disease in the United States, which presents the company with a huge potential market. Lipscombe also highlights the diagnostic pipeline, the strong response to its $8 million capital raise and what to expect in the next three to six months.

© 2022 The Latest StockMarket News and Interviews